ValGenesis is a Santa Clara, California-based software company founded in 2005 that develops digital validation and lifecycle management technology for regulated life sciences organizations. Its AI-enabled Smart GxP platform covers validation, quality and manufacturing workflows, with products including iVal for validation lifecycle management, iClean for cleaning validation, iOps for digital operations and logbooks, iCMC for process development and iCPV for continued process verification. Pharmaceutical, biotechnology and medical-device companies use ValGenesis to replace paper-based validation, improve traceability and compliance, automate regulated workflows and accelerate product delivery. The company says its software is used by 30 of the world's top 50 life sciences companies.
ValGenesis offers candidates the opportunity to build enterprise software for highly regulated pharmaceutical, biotech and medical-device environments, where reliability, security, traceability and compliance are core engineering requirements. The company says its platform is used by 30 of the world's top 50 life sciences companies and has more than 550 employees across seven global offices. Current engineering roles show work across cloud-native .NET, React, Azure, Kubernetes, data engineering and AI/ML, including the expansion of its VAL AI capabilities. Morgan Stanley Expansion Capital invested $24 million in the company, and ValGenesis secured up to $16 million in additional strategic financing in 2025. Candidates in India should note that many current engineering positions are advertised as on-site roles.
Backend
Backend Framework
Frontend
Frontend
Cloud
DevOps
Container Orchestration
Messaging
Messaging
Database
Database
Data Engineering
Data Engineering
Data Processing
Data Analytics
Data Platform
Founder, CEO and Chief Product Strategist of ValGenesis. Before starting the company, Dr. Samy held technical and management roles in biotech, pharmaceutical and medical-device organizations focused on validation and IT. He holds a master's degree in Analytical Chemistry, a Ph.D. in Medical Devices and completed postdoctoral work through the University of Madras and University of Toronto. He also holds a U.S. patent related to validation lifecycle management.
President of ValGenesis since October 2026, responsible for strengthening operations, supporting global growth and advancing long-term strategy. Horn previously served as President and CFO of Seer and spent more than 20 years at Morgan Stanley, where he was a Managing Director in healthcare investment banking. He holds an A.B. from Princeton University and an MBA from Stanford Graduate School of Business.
COO of ValGenesis, responsible for worldwide sales, partnerships and customer growth. Raj has extensive experience selling software to regulated life sciences organizations. Before ValGenesis, he held leadership roles including Senior Director of Industry Solutions at Pilgrim Quality Solutions and Director of Pre-Sales at Infor.
CFO of ValGenesis with experience across private, public, venture-backed and private-equity-backed technology companies. He previously served as SVP of Finance and Accounting at SugarCRM and as CFO of Virtual Instruments, PanTerra Networks and Cassatt. His experience includes financial strategy, fundraising, mergers and acquisitions and scaling technology businesses.
CTO of ValGenesis, leading product engineering and development. Medasani previously served as VP of Engineering and QA at Tanla Platforms, led BluJay Solutions' India Development Center and held engineering and product leadership roles at Oracle in India and the United States across CX, insurance and hospitality products.
ValGenesis
ValGenesis appointed David Horn as president to strengthen its financial and operating foundation, support global growth and help expand the Smart GxP and VAL AI platforms. Horn previously served as President and CFO of Seer and spent more than two decades at Morgan Stanley.
Read articleValGenesis
Eugia Pharmaceuticals deployed ValGenesis as a centralized computer system validation platform across its India operations to standardize validation workflows, automate documentation and improve compliance, traceability and inspection readiness.
Read articleValGenesis
ValGenesis introduced the next generation of VAL, its AI capabilities for regulated validation workflows. The system supports activities including protocol and trace generation, gap assessment, execution review, evidence analysis and anomaly identification while maintaining human oversight and traceability.
Read articleMorgan Stanley
ValGenesis secured strategic financing of up to $16 million from Bridge Bank's Innovation Banking Group to support global expansion and accelerate development of AI-powered validation products.
Read articleNo open roles available
Check back later for new opportunities.
